IQVIA Holdings Inc. (NYSE:IQV) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of IQVIA Holdings Inc. (NYSE:IQV) have earned an average rating of “Moderate Buy” from the twenty-two analysts that are covering the stock, MarketBeat Ratings reports. Five analysts have rated the stock with a hold recommendation, sixteen have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $241.50.

A number of equities research analysts have weighed in on IQV shares. Truist Financial decreased their target price on shares of IQVIA from $263.00 to $216.00 and set a “buy” rating for the company in a research note on Thursday, April 10th. Stephens initiated coverage on IQVIA in a research note on Friday, December 20th. They issued an “overweight” rating and a $250.00 price objective for the company. StockNews.com lowered IQVIA from a “buy” rating to a “hold” rating in a report on Wednesday, March 12th. BTIG Research downgraded IQVIA from a “buy” rating to a “neutral” rating in a research note on Monday, February 3rd. Finally, Citigroup cut their price objective on IQVIA from $225.00 to $210.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Pine Valley Investments Ltd Liability Co raised its stake in IQVIA by 0.5% in the 3rd quarter. Pine Valley Investments Ltd Liability Co now owns 9,481 shares of the medical research company’s stock valued at $2,247,000 after purchasing an additional 50 shares during the last quarter. Howard Capital Management Inc. grew its stake in IQVIA by 4.9% in the 4th quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company’s stock worth $225,000 after acquiring an additional 54 shares during the period. Wealth Enhancement Advisory Services LLC raised its holdings in IQVIA by 1.0% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 5,434 shares of the medical research company’s stock valued at $1,068,000 after acquiring an additional 56 shares during the last quarter. Cypress Wealth Services LLC lifted its stake in shares of IQVIA by 4.8% during the 4th quarter. Cypress Wealth Services LLC now owns 1,243 shares of the medical research company’s stock worth $244,000 after purchasing an additional 57 shares during the period. Finally, Harbor Investment Advisory LLC grew its position in shares of IQVIA by 4.7% in the fourth quarter. Harbor Investment Advisory LLC now owns 1,286 shares of the medical research company’s stock valued at $253,000 after purchasing an additional 58 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Trading Down 1.2 %

NYSE:IQV opened at $149.14 on Friday. IQVIA has a 12 month low of $135.97 and a 12 month high of $252.88. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The company has a 50-day moving average price of $180.02 and a 200-day moving average price of $198.45. The stock has a market cap of $26.29 billion, a price-to-earnings ratio of 19.88, a P/E/G ratio of 1.99 and a beta of 1.46.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Equities analysts predict that IQVIA will post 10.84 EPS for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.